The Similarities and Differences in MF, PV, and ET/Current Available Treatments/Symptom Management
Ruben Mesa, MD, UT Health San AntonioПодробнее
Current Management of Essential Thrombocythemia - Carlos Besses, MDПодробнее
My view on current and future use of JAK inhibitors for ET, PV, and MFПодробнее
The evolving treatment of MF, PV, and ET: aiming for clonal eliminationПодробнее
An Overview of ET, PV and MF Treatment OptionsПодробнее
Understanding MPN Treatment Options | What’s Available for MF, PV, and ET?Подробнее
Risk-adapted treatment of ET & PVПодробнее
Understanding High-Risk vs Low-Risk Disease in PV, ET & MFПодробнее
Current therapy options and clinical outcomes analysis in patients with PVПодробнее
Volume 3 | (2024.01.23) MPN Pathways Webinar Series - Clinical Trials 101Подробнее
Treatment goals in Essential Thrombocythemia and Polycythemia veraПодробнее
Indication for cytoreductive therapy in ET and PV: Do we have it right?Подробнее
MPNs: Differentiating Between ET, PV, and MFПодробнее
What is Personalized Medicine for ET, PV & MF?Подробнее
Diagnosis, Prognosis, and Therapy of True ET vs. Prefibrotic MFПодробнее
Myelofibrosis and P-Vera: Current and Emerging TreatmentsПодробнее
Recent advances in the diagnosis, prognosis and survival predictions of patients with PVПодробнее
My view on current and future use of JAK inhibitors for ET, PV, and MFПодробнее
